Autoimmune Chronic Active Hepatitis

  • Firas H. Al-Kawas


Chronic active hepatitis is a clinicopathologic syndrome caused by a group of heterogeneous disorders that share in common a characteristic histologic picture (Table I). The clinical presentation, natural history, and response to treatment vary widely among the different etiologies. Clinically, the syndrome is defined by persistent necroinflammation in the liver for more than 6 months, as reflected by persistent elevation of serum aminotransferase levels. A group of patients with no viral markers, demonstrating hypergammaglobulinemia and a variety of non-organ-specific immunologic markers have been designated as having autoimmune or lupoid chronic active hepatitis and are responsible for approximately one third of all chronic hepatitis cases.1


Chronic Liver Disease Primary Biliary Cirrhosis Esophageal Varix Chronic Active Hepatitis Chronic Persistent Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seeff LB, Wright EC: An overview and appraisal of the Mayo Clinic trial for chronic active hepatitis, in Czaja AJ, Dickson RE (eds): Chronic Active Hepatitis. The Mayo Clinic Experience. Dekker, New York, 1986, pp. 315–340.Google Scholar
  2. 2.
    Waldenstrom J: Leber Blutproteine und Nahrungsei weiss. Dtsch Gesellsch Verdau Stoffwechselkr 15:113–119, 1950.Google Scholar
  3. 3.
    Bearn AG, Kunkel HG, Slater RJ: The problem of chronic liver disease in young women. Am J Med 21:3–15, 1956.PubMedCrossRefGoogle Scholar
  4. 4.
    MacLachlan MJ, Rodnan GP, Cooper WM, et al: Chronic active (lupoid) hepatitis: A clinical, serological and pathological study of 20 patients. Ann Intern Med 62:425–462, 1965.PubMedGoogle Scholar
  5. 5.
    Joske RA, King WE. The“LE cell”phenomenon in active chronic viral hepatitis. Lancet 2:477–480, 1955.CrossRefGoogle Scholar
  6. 6.
    MacKay IR, Taft LT, Cowling DC: Lupoid hepatitis. Lancet 2:1323–3126, 1956.CrossRefGoogle Scholar
  7. 7.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al: “Lupoid” hepatitis, a non-entity in the spectrum of chronic active liver disease. Gastroenterology 63:458–465, 1972.PubMedGoogle Scholar
  8. 8.
    Czaja AJ, Davis GL, Ludwig J, et al: Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–718, 1983.PubMedGoogle Scholar
  9. 9.
    Mistilis SP, Blackburn CRB: Active chronic hepatitis. Am J Med 48:484–495, 1970.PubMedCrossRefGoogle Scholar
  10. 10.
    Sherlock S: Progress report. Chronic hepatitis. Gut 15:581–597, 1974.PubMedCrossRefGoogle Scholar
  11. 11.
    Czaja AJ: Natural history, clinical features and treatment of autoimmune chronic active hepatitis. Semin Liver Dis 4:1–12, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Lebovics E, Schaffher F, Klion FM, et al: Autoimmune chronic active hepatitis in post menopausal women. Dig Dis Sci 30:824–828, 1985.PubMedCrossRefGoogle Scholar
  13. 13.
    Plotz PH: Asymptomatic chronic hepatitis. Gastroenterology 68:1629–1630, 1975.PubMedGoogle Scholar
  14. 14.
    Hodges JR, Millward-Sadler GH, Wright R: Chronic active hepatitis: The spectrum of disease. Lancet 1:550–552, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Koretz RL, Lewin KJ, Higgins J, et al: Chronic active hepatitis. Who meets treatment criteriaS Dig Dis Sci 25:695–699, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Schaffner F: Autoimmune chronic active hepatitis. Three decades of progress, in Popper H, Schaffner F (eds): Progress in Liver Disease, Vol. VIII. Grune & Stratton, Orlando, Florida, 1986, pp. 485–503.Google Scholar
  17. 17.
    Davis GL, Czaja AJ, Baggenstoss AH, et al: Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc 57:303–309, 1982.PubMedGoogle Scholar
  18. 18.
    Shouval D, Levij IS, Eliakim M: Chronic active hepatitis with cholestatic features. I. A clinical and immunologic study. Am J Gastroenterol 72:542–550, 1979.PubMedGoogle Scholar
  19. 19.
    Doniach D, Roitt IM, Walker JG, et al: Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implication. Clin Exp Immunol 1:237–262, 1966.PubMedGoogle Scholar
  20. 20.
    Meyer Zum Buschenfeld KH, Manns M: Mechanisms of autoimmune liver disease. Semin Liver Dis 4:26–35, 1984.CrossRefGoogle Scholar
  21. 21.
    Thomas HC, Lok ASF: The immunopathology of autoimmune and hepatitis S virus-induced chronic hepatitis. Semin Liver Dis 4:36–46, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Maddrey WC: Subdivisions of idopathic autoimmune chronic active hepatitis. Hepatology 7:1372–1375, 1987.PubMedCrossRefGoogle Scholar
  23. 23.
    Homberg JC, Abuaf N, Bernard O, et al: Chronic active hepatitis associated with anti liver/kidney microsome antibody type 1: A second type of autoimmune hepatitis. Hepatology 7:1333–1339, 1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Galbraith RM, Smith M, MacKenzie RM, et al: High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. S Engl J Med 290:64–69, 1974.Google Scholar
  25. 25.
    Golding PL, Smith M, Williams R: Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med 55:772–782, 1973.PubMedCrossRefGoogle Scholar
  26. 26.
    Mackay IR: Immunological aspects of chronic active hepatitis. Hepatology 3:724–728, 1983.PubMedCrossRefGoogle Scholar
  27. 27.
    Manns M, Gerken G, Kynatsoulis A, et al: Characterization of a new subgroup of autoimmune chronic active hepatitis by auto antibodies against a soluble liver antigen. Lancet 1:292–294, 1987.PubMedCrossRefGoogle Scholar
  28. 28.
    MacKay IR: Genetic aspects of immunologically mediated liver disease. Semin Liver Dis 4:13–25, 1984.PubMedCrossRefGoogle Scholar
  29. 29.
    Eddelston ALWF. Immunology of chronic active hepatitis. Q J Med 55:191–195, 1985.Google Scholar
  30. 30.
    Cook GC, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 158:159–185, 1971.Google Scholar
  31. 31.
    Kirk AP, Jain S, Pocock S, et al: Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis S surface antigen negative chronic active hepatitis. Gut 21:78–83, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al: Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972.PubMedGoogle Scholar
  33. 33.
    Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737, 1973.PubMedCrossRefGoogle Scholar
  34. 34.
    Wright EC, Seeff LB, Berk PD, et al: Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology 73:1422–1430, 1977.PubMedGoogle Scholar
  35. 35.
    Schalm SW, Summerskill WHJ, Go VLW: Prednisone for chronic active liver disease. Pharmakokinetics, including conversion to prednisolone. Gastroenterology 72:910–913, 1977.PubMedGoogle Scholar
  36. 36.
    Penn I, Hammond N, Brettschneider L, et al: Malignant lymphomas in transplant patients. Transplant Proc 1:106–112, 1969.PubMedGoogle Scholar
  37. 37.
    Czaja AJ, Summerskill WHJ. Malignancy in chronic liver disease. Gastroenterology 73:192–193, 1977.PubMedGoogle Scholar
  38. 38.
    DeGroote J, Fevery J, Lepoutre L: Long term followup of chronic active hepatitis of moderate severity. Gut 19:510–513, 1978.CrossRefGoogle Scholar
  39. 39.
    Czaja AJ, Wolf AM, Summerskill WHJ: Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. Gastroenterology 77:629–633, 1979.PubMedGoogle Scholar
  40. 40.
    Jackobovits AW, Gibson PR, Duddley FJ: Primary liver cell carcinoma complicating autoimmune chronic active hepatitis. Dig Dis Sci 26:694–699, 1981.CrossRefGoogle Scholar
  41. 41.
    Burroughs AK, Bassendine MF, Thomas HC, et al: Primary liver cancer in autoimmune chronic liver disease. Br Med J 282:273, 1981.CrossRefGoogle Scholar
  42. 42.
    Czaja AJ, Davis GL, Ludwig J, et al: Complete resolution of inflammatory active following corticosteroid treatment of HBsAg negative chronic active hepatitis. Hepatology 4:622–626, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Hegarty JE, Nouri Aria KT, Portmann B, et al: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3:685–689, 1983.PubMedCrossRefGoogle Scholar
  44. 44.
    Stellon AJ, Portman B, Hegarty JE, Williams R: Randomized controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1:668–670, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Firas H. Al-Kawas
    • 1
  1. 1.Division of Gastroenterology/ Hepatology/Nutrition, Veterans Administration Medical CenterGeorgetown University School of MedicineUSA

Personalised recommendations